Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...
Sotagliflozin won't die, and in the absence of a marketing partner, management is committed to pursuing FDA approval for the heart failure indication on their own. Upcoming studies of rival drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback